The binding of pirenzepine to digitonin-solubilized muscarinic acetylcholine receptors from the rat myocardium

British Journal of Pharmacology
N J BirdsallM Keen

Abstract

The binding of pirenzepine to digitonin-solubilized rat myocardial muscarinic acetylcholine receptors has been examined at 4 degrees C. Solubilization produced only small changes in the binding of N-methylscopolamine and atropine. In contrast to the low affinity binding of pirenzepine found to be present in in the membranes, high affinity binding was detected in the soluble preparation. In both preparations, pirenzepine binding was complex. High affinity pirenzepine binding (KD approximately 3 X 10(-8)M) to the soluble myocardial receptors could be monitored directly using [3H]-pirenzepine. [3H]-pirenzepine-labelled soluble myocardial receptors have a sedimentation coefficient of 11.1 s. This indicates that [3H]-pirenzepine binds predominantly to the uncoupled form of the receptor. However, [3H]-pirenzepine-agonist competition experiments indicated that the high affinity pirenzepine binding sites are capable of coupling with a guanosine 5'-triphosphate (GTP)-binding protein. Pirenzepine affinities for the soluble myocardial receptors were unaffected by their state of association with the GTP-binding proteins found in the heart. The equilibrium binding properties of the soluble cortical and myocardial receptors were very similar...Continue Reading

References

Dec 1, 1985·Biochemical Society Transactions·C P BerrieM Wheatley
Jan 1, 1984·Nihon rinsho. Japanese journal of clinical medicine·S KishimotoA Miyoshi
Oct 14, 1983·European Journal of Pharmacology·E C HulmeJ M Stockton
Aug 1, 1984·British Journal of Pharmacology·C P BerrieE C Hulme
Jan 1, 1983·Journal of Receptor Research·E C HulmeJ Stockton
Mar 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·E BurgisserR J Lefkowitz
Jul 17, 1981·European Journal of Pharmacology·E C HulmeA S Burgen
Jan 1, 1980·British Journal of Pharmacology·D A BrownS Marsh

❮ Previous
Next ❯

Citations

Jan 1, 1988·Pharmacology & Therapeutics·F Mitchelson
Oct 1, 1995·Neurochemistry International·J Musílková, S Tucek
Sep 18, 1990·European Journal of Pharmacology·A P BraunP V Sulakhe
Jun 14, 2013·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Tatsuya Haga
Sep 1, 1989·Journal of Computer-aided Molecular Design·T J MitchellG A Webb
Dec 1, 1987·British Journal of Pharmacology·A D Michel, R L Whiting
Apr 26, 2005·Biophysical Journal·Bryan W BergerClifford R Robinson
May 7, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Turgut Emrah Bozkurt, Inci Sahin-Erdemli
May 22, 1991·Proceedings. Biological Sciences·G D Housley, J F Ashmore
Jul 18, 2002·The Journal of Biological Chemistry·Chi Shing SumJames W Wells
Nov 30, 1988·Biochemical and Biophysical Research Communications·C J van Koppen, M Sokolovsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.